Measurement of bone alkaline phosphatase and relative study with osteosarcoma
- PMID: 24557618
- DOI: 10.1007/s11684-007-0011-9
Measurement of bone alkaline phosphatase and relative study with osteosarcoma
Abstract
The objective of this paper is to explore the value of bone alkaline phosphatase (BALP) for diagnosing osteosarcoma, evaluating the effect of the chemotherapy, judging the prognosis and supervising the relapse and metastasis. The immunoassay was used to check the BALP of the blood serum that was from 42 primary osteosarcoma patients. Alkaline phosphatase (ALP) in blood serum was checked with auto biochemistry equipment. The biopsy tissue and the lesion resected in operation were treated with pathology and histological response was counted. The patients were followed up from five months to 49 months with an average of 24.3 months. Eighteen cases relapsed and transferred, among which, 16 of them were dead, and others were survival to the end of the follow-up. BALP was more sensitive than ALP in diagnosing osteosarcoma (P = 0.015). Fifteen cases decreased to normal value in ALP after preoperative chemotherapy, and 34 cases decreased in BALP. Both ALP and BALP in all cases decreased to normal value in post-operative. There was significant difference in positive correlation between the decrease of BALP and the increase of histological response (P = 0.001, r = 0.642). In the follow-up, there was significant difference in BALP between the group of relapse and transfer and the group of free disease survival (P = 0.000). As a check marker in blood serum, BALP, reflecting the process of ossification, has a higher sensitivity than ALP. It has applied value in the diagnosis of osteosarcoma, reflection of the effect of chemotherapy and forecast the prognosis.
Similar articles
-
The levels of bone alkaline phosphatase (BALP) and soluble epidermal growth factor receptor-2 (ECD/HER-2) in pediatric patients with osteosarcoma during clinical treatment.Dev Period Med. 2018;22(1):58-64. doi: 10.34763/devperiodmed.20182201.5864. Dev Period Med. 2018. PMID: 29641422 Free PMC article.
-
Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma.Oncology. 1996 Jul-Aug;53(4):275-80. doi: 10.1159/000227573. Oncology. 1996. PMID: 8692530
-
Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.J Nephrol. 2017 Apr;30(2):255-262. doi: 10.1007/s40620-016-0292-7. Epub 2016 Mar 18. J Nephrol. 2017. PMID: 26994005
-
[Markers of bone formation in children with osteosarcoma].Med Wieku Rozwoj. 2004 Apr-Jun;8(2 Pt 1):235-43. Med Wieku Rozwoj. 2004. PMID: 15738599 Polish.
-
Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.BMC Vet Res. 2012 May 15;8:56. doi: 10.1186/1746-6148-8-56. BMC Vet Res. 2012. PMID: 22587466 Free PMC article. Review.
Cited by
-
A new phosphorimetry for the determination of trace alkaline phosphatase using multi-wall carbon nanotubes and its diagnosis of human diseases.J Fluoresc. 2010 Jul;20(4):933-41. doi: 10.1007/s10895-010-0639-8. Epub 2010 Apr 8. J Fluoresc. 2010. PMID: 20376694
-
The levels of bone alkaline phosphatase (BALP) and soluble epidermal growth factor receptor-2 (ECD/HER-2) in pediatric patients with osteosarcoma during clinical treatment.Dev Period Med. 2018;22(1):58-64. doi: 10.34763/devperiodmed.20182201.5864. Dev Period Med. 2018. PMID: 29641422 Free PMC article.
References
LinkOut - more resources
Research Materials